Full Name
Jianbiao Zhou
Variants
Zhou J.
Zhou, J.
Zhou, J.B.
Zhou J
Zhou Jianbiao
Zhou, Jianbiao
 
 
 
Email
csizjb@nus.edu.sg
 

Publications

Results 1-20 of 47 (Search time: 0.011 seconds).

Issue DateTitleAuthor(s)
12018A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphataseZhou, J ; Toh, S.H.-M; Chan, Z.-L; Quah, J.Y; Chooi, J.-Y ; Tan, T.Z ; Chong, P.S.Y ; Zeng, Q ; Chng, W.-J 
22015Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: From molecular pathogenesis to therapeutic targetZhou J. ; Ching Y.Q. ; Chng W.-J. 
32008ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograftJasinghe, V.J. ; Xie, Z. ; Zhou, J. ; Khng, J.; Poon, L.-F. ; Senthilnathan, P. ; Chen, C.-S. ; Albert, D.H.; Davidsen, S.K.
42009ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedsideZhou, J. ; Chen, C.-S. ; Goh, B.-C.; Albert, D.H.
51-Mar-2011Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profilingNg, Siok-Bian ; Selvarajan, Viknesvaran; Huang, Gaofeng; Zhou, Jianbiao ; Feldman, Andrew L; Law, Mark; Kwong, Yok-Lam; Shimizu, Norio; Kagami, Yoshitoyo; Aozasa, Katsuyuki; Salto-Tellez, Manuel; Chng, Wee-Joo 
614-Jul-2011Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-B: Implication in breast cancer metastasisBist, P.; Leow, S.C.; Phua, Q.H.; Shu, S.; Zhuang, Q.; Loh, W.T.; Nguyen, T.H.; Zhou, J.B. ; Hooi, S.C.; Lim, L.H.K.
71-Sep-2020ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.Zhou, Jianbiao ; Yiying Quah, Jessie ; Ng, Yvonne ; Chooi, Jing-Yuan ; Hui-Min Toh, Sabrina ; Lin, Baohong; Zea Tan, Tuan ; Hosoi, Hiroki ; Osato, Motomi ; Seet, Qihui; Ooi, Lisa AG; Lindmark, Bertil; McHale, Mark; Chng, Wee-Joo 
2811-Jul-2018BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemiaZhou Y.; Zhou J. ; Lu X.; Tan T.-Z. ; Chng W.-J. 
91-Mar-2022Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple MyelomaZhou, Jianbiao ; Chng, Wee-Joo 
1018-Feb-2021Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myelomaXiong, Sinan; Chng, Wee-Joo ; Zhou, Jianbiao 
112011Determinants of sensitivity to DZNep induced Apoptosis in multiple myeloma cellsXie, Z. ; Bi, C.; Cheong, L.L.; Liu, S.C.; Huang, G. ; Zhou, J. ; Yu, Q.; Chen, C.-S.; Chng, W.J.
12Feb-2012Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in miceGuo, K.; Tang, J.P.; Jie, L.; Al-Aidaroos, A.Q.O.; Hong, C.W.; Tan, C.P.B.; Park, J.E.; Varghese, L.; Feng, Z.; Zhou, J. ; Chng, W.J.; Zeng, Q. 
132009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J. ; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
142015Functional characterization of D9, a novel deazaneplanocin a (DZNep) analog, in targeting acute myeloid leukemia (AML)Jiang, Xia; Lim, Cheryl Zi Hui; Li, Zhimei; Lee, Puayleng; Yatim, Siti Maryam J. M.; Guan, Peiyong; Li, Juntao; Zhou, Jianbiao ; Pan, Jingxuan; Chng, Wee Joo ; Chai, Li Lin Christina ; Yu, Qiang 
152015Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myelomaBi, C; Chung, T.-H ; Huang, G ; Zhou, J ; Yan, J ; Ahmann, G.J; Fonseca, R; Chng, W.J 
1615-Sep-2019IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple MyelomaChong, Phyllis SY ; Zhou, Jianbiao ; Lim, Julia SL ; Hee, Yan Ting; Chooi, Jing-Yuan ; Chung, Tae-Hoon ; Tan, Zea Tuan ; Zeng, Qi ; Waller, Daniel D; Sebag, Michael; Chng, Wee-Joo 
172008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J. ; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
182008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J.; Bi, C.; Poon, L.F.; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
192017Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemiaZhou, J ; Bi, C; Ching, Y.Q ; Chooi, J.-Y ; Lu, X; Quah, J.Y ; Toh, S.H.-M ; Chan, Z.-L; Tan, T.Z ; Chong, P.S ; Chng, W.-J 
202010ITIH3 Is a potential biomarker for early detection of gastric cancerChong, P.K. ; Lee, H.; Zhou, J. ; Liu, S.-C.; Loh, M.C.S. ; Wang, T.T. ; Lim, Y.P. ; Chan, S.P.; Smoot, D.T.; Ashktorab, H.; So, J.B.Y. ; Lim, K.H.; Yeoh, K.G.